Want to see IN:TORNTPHARM full AI Analyst Report?
TORNTPHARM Stock Chart & Stats
₹4959.80
₹58.00(1.17%)
At close: 4:00 PM EDT
₹4959.80
₹58.00(1.17%)
Day’s Range― - ―
52-Week Range₹3,480.00 - ₹5,249.95
Previous CloseN/A
Volume267.59K
Average Volume (3M)7.49K
Market Cap
₹1.86T
Enterprise Value₹1.65M
Total Cash (Recent Filing)₹23.55B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)76.0
Beta0.47
Next Earnings
Oct 28, 2026EPS Estimate
17.45Next Dividend Ex-DateN/A
Dividend Yield0.31%
Share Statistics
EPS (TTM)64.44
Shares Outstanding380,354,250
10 Day Avg. Volume2,743
30 Day Avg. Volume7,494
Financial Highlights & Ratios
PEG Ratio5.00
Price to Book (P/B)17.02
Price to Sales (P/S)10.22
P/FCF Ratio73.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)68.65
Revenue Forecast (FY)₹196.39B
Bulls Say, Bears Say
Bulls Say
Sustained Revenue GrowthSustained revenue expansion indicates strengthening demand and market reach, supporting scale benefits across Torrent’s branded-generic portfolio and providing a durable base for future earnings growth.
Improving ProfitabilityThe long-term improvement in net margins and consistently healthy operating margins support earnings quality and indicate that the company has retained meaningful profitability as revenue has expanded.
Strong Free Cash FlowConsistently positive operating cash flow and substantial free cash flow demonstrate the business can convert operations into funding for investment, debt reduction, and shareholder returns over time.
Bears Say
Gross Margin VolatilityThe sharp gross-margin decline suggests exposure to product mix, pricing, or input-cost pressures. If persistent, it could limit operating leverage and make future profit growth less predictable.
Uneven Cash ConversionUneven conversion of accounting earnings into operating cash can signal working-capital or earnings-quality pressure. Continued volatility could reduce financial flexibility despite generally strong cash generation.
Balance-Sheet Transparency RiskThe unusually large asset increase creates comparability and asset-quality uncertainty because the available data does not explain its composition. This warrants monitoring of future disclosures and capital allocation.
Torrent Pharmaceuticals Ltd News
TORNTPHARM FAQ
What was Torrent Pharmaceuticals Ltd’s price range in the past 12 months?
Torrent Pharmaceuticals Ltd lowest stock price was ₹3480.00 and its highest was ₹5249.95 in the past 12 months.
What is Torrent Pharmaceuticals Ltd’s market cap?
Torrent Pharmaceuticals Ltd’s market cap is ₹1.86T.
When is Torrent Pharmaceuticals Ltd’s upcoming earnings report date?
Torrent Pharmaceuticals Ltd’s upcoming earnings report date is Oct 28, 2026 which is in 65 days.
How were Torrent Pharmaceuticals Ltd’s earnings last quarter?
Torrent Pharmaceuticals Ltd released its earnings results on Jul 30, 2026. The company reported ₹15.4 earnings per share for the quarter, beating the consensus estimate of ₹14.95 by ₹0.45.
Is Torrent Pharmaceuticals Ltd overvalued?
According to Wall Street analysts Torrent Pharmaceuticals Ltd’s price is currently Overvalued.
Does Torrent Pharmaceuticals Ltd pay dividends?
Torrent Pharmaceuticals Ltd pays a Semiannually dividend of ₹9 which represents an annual dividend yield of 0.31%. See more information on Torrent Pharmaceuticals Ltd dividends here
What is Torrent Pharmaceuticals Ltd’s EPS estimate?
Torrent Pharmaceuticals Ltd’s EPS estimate is 17.45.
How many shares outstanding does Torrent Pharmaceuticals Ltd have?
Torrent Pharmaceuticals Ltd has 380,354,250 shares outstanding.
What happened to Torrent Pharmaceuticals Ltd’s price movement after its last earnings report?
Torrent Pharmaceuticals Ltd reported an EPS of ₹15.4 in its last earnings report, beating expectations of ₹14.95. Following the earnings report the stock price went down -0.138%.
Which hedge fund is a major shareholder of Torrent Pharmaceuticals Ltd?
Currently, no hedge funds are holding shares in IN:TORNTPHARM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Torrent Pharmaceuticals Ltd
Torrent Pharmaceuticals Limited operates as a global pharmaceutical entity, managing the entire process from the discovery and development of generic drug formulations to their production and distribution. Its commercial activities extend across key markets such as India, the United States, Germany, and Brazil, alongside various other international territories. The company boasts a broad product catalog, offering treatments for a wide array of medical conditions. This includes therapies for cardiovascular diseases, central nervous system disorders, gastrointestinal issues, women's health concerns, diabetes, pain management, gynecological ailments, oncology, and anti-infective medications. Additionally, Torrent Pharma supplies essential vitamins, minerals, and other nutritional supplements. Beyond its proprietary offerings, the firm also provides contract manufacturing services to other companies. During the COVID-19 pandemic, it demonstrated its commitment by securing licensing agreements for crucial treatments like Baricitinib, Molnupiravir, and Paxlovid. Established in 1959, the company originally operated under the name Trinity Laboratories before officially becoming Torrent Pharmaceuticals Limited in 1971. Its corporate headquarters are located in Ahmedabad, India. Ultimately, Torrent Pharmaceuticals Limited functions as a subsidiary of Torrent Investments Private Limited.
Technical Analysis
Dr. Reddy's Laboratories Ltd.
―
Lupin Limited
―
Mankind Pharma Ltd.
―
Sun Pharmaceutical Industries Limited
―
Zydus Lifesciences Limited
―







